ORPHA:1679
Diphtheria
Publications
158,078
Trials
258
Interventional, condition-specific
Researchers
1,521
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare bacterial infectious disease characterized by an affliction of the upper respiratory tract mediated by the toxin of Corynebacterium diphtheriae. Symptoms include formation of an inflammatory pseudomembrane, fever, sore throat, headaches, coughing, dysphagia, dyspnea, and prominently swollen cervical lymph nodes. The disease may lead to respiratory failure and severe toxin-mediated damage of internal organs, including the heart and kidneys. A cutaneous form of diphtheria is more common in tropical climates and usually follows an indolent course.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005504
- MeSH:D004165
- UMLS:C0012546
- NCIT:C34541
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
158,078 matched papers (52,619 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
258 matched on ClinicalTrials.gov (17 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
8
Drugs / clinical candidates · MONDO_0005504
- PENTETIC ACID·phase 3
- TECHNETIUM TC 99M PENTETATE·phase 3
- TRALOKINUMAB·phase 2
- BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ·approval
- BORDETELLA PERTUSSIS PERTACTIN AUTOTRANSPORTER·approval
- DIPHTHERIA TOXOID·approval
- HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN·approval
- TETANUS TOXOID·approval
CTD chemicals (MyDisease.info)
7 associated chemicals. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Daptomycin · therapeutic
- Imipenem · therapeutic
- Linezolid · therapeutic
- Piperacillin, Tazobactam Drug Combination · therapeutic
- quinupristin-dalfopristin · therapeutic
- Rifampin · therapeutic
- telavancin · therapeutic
Literature
Is anyone studying this?
158,078
158,078 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
158,078 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
52,619 in the last 10 years · low confidence
Phrase hits: 158,078 · MeSH hits: 0
Who's working on it?
1,521
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang X7 papers · 2026
CanSino Biologics Inc., Tianjin, People's Republic of China.
Papers in Europe PMC - 02Senoh M6 papers · 2026
Department of Bacteriology II, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Tokyo, Japan.
Papers in Europe PMC - 03Wang Y6 papers · 2026
State Key Laboratory of Membrane Biology, School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing, China.
Papers in Europe PMC - 04Iwaki M5 papers · 2026
Department of Bacteriology II, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Tokyo, Japan.
Papers in Europe PMC - 05Kimura M5 papers · 2026
Department of Bacteriology II, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Tokyo, Japan.
Papers in Europe PMC - 06Berger A3 papers · 2026
German National Consiliary Laboratory for Diphtheria (NCLD), EU Reference Laboratory for Public Health on Diphtheria and Pertussis (EURL-PH-DIPE), WHO Collaborating Centre for Diphtheria, Bavarian Health and Food Safety Authority (LGL), Oberschleißheim, Germany.
Papers in Europe PMC - 07Brisse S3 papers · 2026
Biodiversity and Epidemiology of Bacterial Pathogens Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Papers in Europe PMC - 08Chen J3 papers · 2026
Yiwu Center for Disease Control and Prevention, Jinhua, China.
Papers in Europe PMC - 09Crestani C3 papers · 2026
Biodiversity and Epidemiology of Bacterial Pathogens Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Papers in Europe PMC - 10Kim H3 papers · 2026
Department of Bacteriology II, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Tokyo, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
258
interventional trials for this specific condition
258 interventional trials matched this specific condition name; 17 currently recruiting in our sample.
Data as of 11 September 2026
258 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.5th percentile).
low confidence · 99.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
258 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06184542·RECRUITING·Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
Not reviewed·Conditions: Diphtheria · Tetanus · Pertussis·Matched via name phrase
- NCT06815250·RECRUITING·Enhancing Maternal Vaccine Knowledge and Uptake: The InTroDuce-Programme Trial
Not reviewed·Conditions: Vaccination Uptake · Knowledge · Tetanus, Diphtheria and Acellular Pertussis Vaccination · Influenza·Matched via name phrase
- NCT07097012·RECRUITING·Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
Not reviewed·Conditions: RSV · Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination · Pregnancy · Healthy·Matched via name phrase
- NCT07005726·ENROLLING BY INVITATION·BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Not reviewed·Conditions: Infant Morbidity · Infant Mortality · Non-Specific Effects of Vaccines · BCG·Matched via name phrase
- NCT06135636·RECRUITING·Assessing Interventions to Increase Tdap Acceptance for Non-birthing Partners in Pregnancy
Not reviewed·Conditions: Non-birthing Partner Vaccination in Pregnancy · Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination · Vaccine Exposure During Pregnancy·Matched via name phrase
- NCT07203755·RECRUITING·Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
Not reviewed·Conditions: Diphtheria, Tetanus and Acellular Pertussis · Epidemic Meningitis · Haemophilus Influenzae Type B Infection·Matched via name phrase
- NCT07418372·NOT YET RECRUITING·Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
Not reviewed·Conditions: Tetanus, Diphtheria and Acellular Pertussis Vaccination · Tetanus · Diphtheria · Pertussis·Matched via name phrase
- NCT07112144·RECRUITING·Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Not reviewed·Conditions: Prevent Whooping Cough · Prevent Diphtheria · Prevent Tetanus·Matched via name phrase
- NCT06997627·RECRUITING·A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
Not reviewed·Conditions: Tetanus-diphtheria-acellular Pertussis (Tdap)·Matched via name phrase
- NCT07596173·RECRUITING·A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years
Not reviewed·Conditions: Diphtheria-Tetanus-acellular Pertussis Vaccines·Matched via name phrase
- NCT06605755·RECRUITING·Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Not reviewed·Conditions: Pertussis · Diphtheria · Tetanus · Haemophilus Influenzae Type B Infection·Matched via name phrase
- NCT07492303·NOT YET RECRUITING·A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
Not reviewed·Conditions: Pertussis (Whooping Cough) · Diphtheria · Tetanus·Matched via name phrase
- NCT06618196·NOT YET RECRUITING·Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
Not reviewed·Conditions: Diphtheria · Tetanus · Pertussis · Hepatitis B·Matched via name phrase
- NCT06344065·RECRUITING·Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants
Not reviewed·Conditions: Healthy Volunteers·Matched via name phrase
- NCT06947499·RECRUITING·A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
Not reviewed·Conditions: Diphtheria · Tetanus · Pertussis · Hepatitis B·Matched via name phrase
Observational and natural-history studies
23 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 56 · after dedupe 56 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 56 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (56)
- ctis·2025-524635-39-00·Authorised·An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)
skipped — LLM skipped (--skip-llm)
- ctis·2025-521752-26-00·Authorised, ongoing·A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
skipped — LLM skipped (--skip-llm)
- ctis·2025-522406-20-00·Authorised, recruiting·A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
skipped — LLM skipped (--skip-llm)
- ctis·2022-503070-36-00·Authorised, ongoing·C1091009 - A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS
skipped — LLM skipped (--skip-llm)
- ctis·2023-509124-18-00·Authorised, recruiting·B7451031 - A Phase 3, Multicenter, Long-Term, Open-Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis
skipped — LLM skipped (--skip-llm)
- ctis·2023-509121-51-00·Authorised, ongoing·B7451023 - A 16-Week, Multicenter, Interventional, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate Efficacy and Safety of Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
skipped — LLM skipped (--skip-llm)
- ctis·2023-507600-32-00·Authorised, recruiting·A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2-arm study to
investigate the safety and immunogenicity of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers
skipped — LLM skipped (--skip-llm)
- ctis·2023-510465-10-00·Expired·A parallel-group prevention, Phase II, partially blinded, multi-stage study to investigate the immunogenicity and safety of Pentavalent Meningococcal ABCYW Vaccine formulations compared with licensed meningococcal vaccines when administered alone in healthy children (2 to 9 years of age) or concomitantly with routine pediatric vaccines in toddlers (12 to 15 months of age) and infants (2 months of age).
skipped — LLM skipped (--skip-llm)
- ctis·2023-508563-73-00·Authorised·A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN-2) when 1 Dose is Administered Concomitantly with the TDaP Vaccine in Healthy Non-pregnant Women 18 to 49 years of age Compared to when Each Vaccine is Administered Alone
skipped — LLM skipped (--skip-llm)
- ctis·2024-517893-73-00·Cancelled·Maternal determinants of infant immunity to pertussis (MADI-02)
skipped — LLM skipped (--skip-llm)
- ctis·2023-507906-15-00·Expired·An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
skipped — LLM skipped (--skip-llm)
- ctis·2023-508416-35-00·Cancelled·A phase 4, randomised vaccination study in healthy adults to investigate the effects of acellular pertussis vaccine on colonisation with Bordetella pertussis using controlled human infection (KIM-study)
skipped — LLM skipped (--skip-llm)
- ctis·2024-511478-56-00·Cancelled·dTap booster vaccination of health care workers (HC dTap)
skipped — LLM skipped (--skip-llm)
- ctis·2024-510974-25-00·Cancelled·A Phase IV, Multicenter, Open-Label Study Evaluating B-Cell Levels in Infants Potentially Exposed to Ocrelizumab During Pregnancy – The MINORE Study
skipped — LLM skipped (--skip-llm)
- ctis·2023-506449-40-00·Cancelled·A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants
skipped — LLM skipped (--skip-llm)
- ctis·2023-504331-41-00·Expired·A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and long-term safety of dupilumab in children 2 to <6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17148628·Not yet recruiting·A study to evaluate the tolerability and the effects on the immune system of a tetanus and diphtheria vaccine which does not need any cold chain distribution or storage
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16504454·Recruiting·A study to see if a new 6-in-1 (hexavalent) vaccine is effective and safe for babies in countries with polio
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98920861·No longer recruiting·A study to evaluate the safety and effects on the immune system of a tetanus and diphtheria vaccine which does not need any cold chain distribution or storage
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65855590·Recruiting·Bivalent vaccination against Salmonella Typhi and Paratyphi A
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89126536·Recruiting·The MAMA Study: Looking at the effects of stopping or continuing biologics for the treatment of inflammatory arthritis in pregnancy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN55932023·No longer recruiting·Study of a virtual reality intervention for pain and anxiety control in pediatric vaccination
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57717892·No longer recruiting·Safety and immune response of the malaria vaccine, R21/Matrix-M™, in Thai adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN60488657·No longer recruiting·New 6-in-1 vaccine study to guide UK vaccine policy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN80067058·No longer recruiting·Comparison of Tonsilgon N and local herbal anti-inflammatory medicine in patients with tonsillitis
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Diphtheria — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Diphtheria"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Diphtheria"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 258 interventional · 23 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (158078) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T17:58:04.864Z
